Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
An already-elevated baseline IGF-1 is a reason not to push the axis higher, and because GH antagonizes insulin, glucose handling deserves attention in patients with diabetes or prediabetes
Weight, Safety, and Common Effects Basal insulins may cause modest weight increases over time, especially during intensive titration
Looking forward, the GLP-1 diabetes treatment drugs market is expected to sustain exceptionally strong growth, with market values reaching USD 20,250.0 million by 2030 and eventually USD 62,543.2 million by 2035, reflecting a CAGR of 25.3%
Acid reflux is another side effect that some patients experience